Ocular Therapeutix Q1 2024 Adj EPS $(0.28) Misses $(0.19) Estimate, Sales $14.774M Miss $15.414M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix reported Q1 2024 adjusted EPS of $(0.28), missing the $(0.19) estimate, with sales of $14.774M also missing the $15.414M estimate. This represents a 10.47% increase in sales compared to the same period last year.
May 07, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ocular Therapeutix missed Q1 2024 EPS and sales estimates, reporting a larger loss per share and slightly lower sales than expected, though sales have increased compared to last year.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the year-over-year sales increase may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100